BioSpace News Archive

Nuvectis Pharma, Inc. today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the H.C. Wainwright BioConnect Investor Conference at the NASDAQ world headquarters in New York City.

PDS Biotechnology Corporation, a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, announced the presentation of updated data from the VERSATILE-002 study at the 2023 ASCO® Annual Meeting being held June 2-6 in Chicago.

Scopio Labs today announced the publication of a new study that examines the impact of implementing remote* digital microscopy for peripheral blood smear (PBS) analysis.

Innoblative Designs, Inc announced today that it received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for the company’s SIRA™ RFA Electrosurgical Device (SIRA).

CinRx Pharma today announced that the first study participant has been dosed in CinDome Pharma’s Phase 2 envision3D study of deudomperidone (CIN-102) in patients with diabetic gastroparesis.

Seagen Inc. (Nasdaq:SGEN) (Seagen or the Company) reported financial results today for the first quarter ended March 31, 2023.

Aytu BioPharma, Inc. received U.S. Food & Drug Administration (“FDA”) approval of the Adzenys XR-ODT® (“Adzenys”) Prior Approval Supplement (“PAS”).

INOVIO today announced that an abstract has been accepted for oral presentation on INO-3107 for the treatment of Recurrent Respiratory Papillomatosis (RRP) at this year’s American Broncho-Esophagological Association (ABEA) program at the Combined Otolaryngology Spring Meetings (COSM) in Boston, Massachusetts.

Takeda today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its Biologics License Application (BLA) resubmission for the investigational subcutaneous (SC) administration of Entyvio® (vedolizumab) for maintenance therapy in adults with moderately to severely active ulcerative colitis (UC) after induction therapy with Entyvio intravenous.

Tavros Therapeutics, Inc. and OpenBench, Inc. today announced the companies have entered into a collaboration agreement to discover small molecule modulators of up to five oncology targets across an initial 18-month term.